Comparable stake leader
GEODE CAPITAL MANAGEMENT, LLC
SEC ownership of Anbio Biotechnology
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001982708.
Disclosed value leader
GEODE CAPITAL MANAGEMENT, LLC
Comparable rows
0/8
Latest evidence
31 Mar 2026
- Public ticker
- NNNN on Nasdaq
- Parsed ownership sources
-
13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
GEODE CAPITAL MANAGEMENT, LLC
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001982708
- Issuer location
- Frankfurt Am Main, Germany
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Anbio Biotechnology (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
GEODE CAPITAL MANAGEMENT,...
Disclosed value leader
GEODE CAPITAL MANAGEMENT,...
Comparable rows
0/8
Latest evidence
31 Mar 2026
13F
Highest disclosed value: $661,851
8 rows are not safely comparable across share classes.
Quick read
GEODE CAPITAL MANAGEMENT, LLC has the largest disclosed position value at $661.9K.
0 of 8 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens GEODE CAPITAL MANAGEMENT, LLC's linked filing trail.
Disclosed position value
Top 5
GEODE CAPITAL MANAGEMENT, LLC
$661.9K
BNP PARIBAS FINANCIAL MARKETS
$267.2K
MORGAN STANLEY
$188.5K
UBS Group AG
$162.8K
EverSource Wealth Advisors, LLC
$6.8K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 8 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$661,851
25,763 shares
|
— | 31 Mar 2026 |
| BNP PARIBAS FINANCIAL MARKETS |
13F
Company
|
—
class O/S missing
|
$267,176
10,400 shares
|
— | 31 Mar 2026 |
| MORGAN STANLEY |
13F
Company
|
—
class O/S missing
|
$188,513
7,338 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$162,849
6,339 shares
|
— | 31 Mar 2026 |
| EverSource Wealth Advisors, LLC |
13F
Company
|
—
class O/S missing
|
$6,834
266 shares
|
— | 31 Mar 2026 |
| WELLS FARGO & COMPANY/MN |
13F
Company
|
—
class O/S missing
|
$2,569
100 shares
|
— | 31 Mar 2026 |
| Bare Financial Services, Inc |
13F
Company
|
—
class O/S missing
|
$385
15 shares
|
— | 31 Mar 2026 |
| Blue Trust, Inc. |
13F
Company
|
—
class O/S missing
|
$128
5 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 08 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-7 of 7 reporting-owner rows connected to Anbio Biotechnology. Open a relationship link for the CIK-to-CIK filing trail.
Rows
7
Largest Forms 3/4/5 holder
Cany Xu
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Cany Xu | Director | Mixed | 18 Mar 2026 | |||
| Chris Tian | Cbo | Mixed | 18 Mar 2026 | |||
| Michael Lau | Ceo | Mixed | 18 Mar 2026 | |||
| Nancy Hartzler | Director | Mixed | 18 Mar 2026 | |||
| Suki Song | Cfo | Mixed | 18 Mar 2026 | |||
| David H. Hsu | Director | Mixed | 18 Mar 2026 | |||
| Michael W.c Zhang | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Anbio Biotechnology
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.